KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Tahamtan Ahmadi, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Sonja Zweegman

Nat Med 31(4) 1195-1202

PMID39910273
PMCIDPMC12003169
DOI10.1038/s41591-024-03485-7
发表日期2025-02-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10-5 by next-generation sequencing. Major secondary endpoints included complete response (CR) or better (≥CR) rate, progression-free survival and sustained MRD-negativity rate at 10-5. At a median follow-up of 58.7 months, the MRD-negativity rate was 60.9% with D-VRd versus 39.4% with VRd (odds ratio, 2.37; 95% confidence interval (CI), 1.58-3.55; P < 0.0001). Rates of ≥CR (81.2% versus 61.6%; P < 0.0001) and sustained MRD negativity (≥12 months; 48.7% versus 26.3%; P < 0.0001) were significantly higher with D-VRd versus VRd. Risk of progression or death was 43% lower for D-VRd versus VRd (hazard ratio, 0.57; 95% CI, 0.41-0.79; P = 0.0005). Adverse events were consistent with the known safety profiles for daratumumab and VRd. Combining daratumumab with VRd produced deeper and more durable MRD responses versus VRd alone. The present study supports D-VRd quadruplet therapy as a new standard of care for transplant-ineligible or transplant-deferred NDMM. ClinicalTrials.gov registration: NCT03652064 .

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Extended Data Fig. 5

Overall survival censoring death due to COVID-19. Panel A censors death due to COVID-19, and Panel B considers COVID-19 as a competing risk (ie, considers COVID death as a competing event and non-COVID death as the event of interest). D-VRd, subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone; VRd, bortezomib/lenalidomide/dexamethasone.

A

overall survival censoring death due to COVID-19

Extended Data Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
B

cumulative overall survival event rate censoring COVID-19 death as competing risk

Extended Data Fig. 5 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(9,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1CONSORT patient flow diagram. Patient disposition at the data cutoff date of 7 May 2024.
非 KM Figure
Fig. 2MRD-negativity rates. a , The primary endpoint of overall MRD-negativity rates in the intention-to-treat population. The overall MRD-negativity rate was defined as the proportion of patients who achieved ≥CR and MRD negativity (at or below a sensitivity threshold of 10 − 5 ) after randomization but before disease progression, subsequent antimyeloma therapy or both. b , An exploratory analysis of the MRD-negativity rate at or below a sensitivity threshold of 10 − 6 . c , Sustained MRD-negativity rate in the intention-to-treat population. The sustained MRD-negativity rate was defined as the proportion of patients who achieved ≥CR and MRD-negative status (at or below a sensitivity threshold of 10 − 5 ) at two examinations a minimum of 1 year apart without MRD-positive status in between. MRD status was assessed using bone marrow samples and evaluated using a next-generation sequencing assay (clonoSEQ assay, v.2.0; Adaptive Biotechnologies) in accordance with International Myeloma Working Group guidelines for assessing MRD 25 . The Mantel–Haenszel estimate of the common odds ratio for stratified tables was used. The stratification factors were ISS disease stage (I, II or III) and age/transplant eligibility (<70 years and transplant ineligible, <70 years and transplant deferred or ≥70 years). An odds ratio >1 indicates an advantage for D-VRd. The P value (two sided) was calculated using a Fisher’s exact test.
非 KM Figure
Fig. 3PFS. The results of the Kaplan–Meier estimates of PFS among patients in the intention-to-treat population. The final analysis of PFS was performed after 162 events of disease progression or death occurred. Of these, eight were censored as a result of missing two or more consecutive disease evaluations preceding the event. The P value was calculated using the stratified log(rank test).
非 KM Figure
Fig. 4≥CR rates. ≥CR rates in the intention-to-treat population. The tumor response was assessed using a validated computer algorithm in accordance with the International Myeloma Working Group response criteria 26 . Complete response (CR) or stringent CR (sCR) was achieved at any time during the trial. The Mantel–Haenszel estimate of the common odds ratio for stratified tables was used. The stratification factors were ISS disease stage (I, II or III) and age/transplant eligibility (<70 years and transplant ineligible, <70 years and transplant deferred or ≥70 years). An odds ratio >1 indicates an advantage for D-VRd. The P value (two sided) was calculated using the Cochran–Mantel–Haenszel χ 2 test. PR, partial response; VGPR, very good partial response.
非 KM Figure
Extended Data Fig. 1Prespecified subgroup analysis of overall MRD-negativity rate. Shown are the results of an analysis of overall MRD-negativity rate in prespecified subgroups in the intention-to-treat population. Data are presented as odds ratios and 95% CIs. Overall MRD-negativity rate was defined as the proportion of patients who achieved complete response or better and MRD negativity (at or below a sensitivity threshold of 10 –5 ) after randomization but prior to disease progression, subsequent antimyeloma therapy or both. The ISS consists of three stages, with higher stages indicating more severe disease: stage I, serum β 2 -microglobulin level <3.5 mg per liter (300 nmol per liter) and albumin level ≥3.5 g per deciliter; stage II, neither stage I or III; and stage III, serum β 2 -microglobulin level ≥5.5 mg per liter (≥470 nmol per liter). Cytogenetic risk was assessed by fluorescence in situ hybridization. High risk was defined as the presence of del(17p), t(4;14) and/or t(14;16). Indeterminate includes patients with missing or unevaluable samples. CI, confidence interval; D-VRd, subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; MRD, minimal residual disease; VRd, bortezomib/lenalidomide/dexamethasone.
非 KM Figure
Extended Data Fig. 2Cumulative incidence of MRD negativity. Shown are the results of the cumulative incidence of MRD negativity. The overall MRD-negativity rate was defined as the proportion of patients who achieved complete response or better and MRD negativity (at or below a sensitivity threshold of 10 –5 ) after randomization but prior to disease progression, subsequent antimyeloma therapy or both. D-VRd, subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone; MRD, minimal residual disease; VRd, bortezomib/lenalidomide/dexamethasone.
非 KM Figure
Extended Data Fig. 3Prespecified subgroup analysis of progression-free survival. Shown are the results of an analysis of progression-free survival in prespecified subgroups in the intention-to-treat population. Data are presented as hazard ratios and 95% CIs. The ISS consists of three stages, with higher stages indicating more severe disease: stage I, serum β 2 -microglobulin level <3.5 mg per liter (300 nmol per liter) and albumin level ≥3.5 g per deciliter; stage II, neither stage I or III; and stage III, serum β 2 -microglobulin level ≥5.5 mg per liter (≥470 nmol per liter). Cytogenetic risk was assessed by fluorescence in situ hybridization. High risk was defined as the presence of del(17p), t(4;14) and/or t(14;16). Indeterminate includes patients with missing or unevaluable samples. CI, confidence interval; D-VRd, subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone. ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; NE, could not be estimated; VRd, bortezomib/lenalidomide/dexamethasone.
非 KM Figure
Extended Data Fig. 4Overall survival. Shown are the results of the Kaplan–Meier estimates of overall survival among patients in the intention-to-treat population. D-VRd, subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone; VRd, bortezomib/lenalidomide/dexamethasone.
非 KM Figure
Extended Data Fig. 6Quality of life. Shown are the results of quality of life in the intention-to-treat population based on the EORTC QLQ-C30 global health status domain score. Data are presented as mean values ± SE. Scores range from 0–100, with higher scores indicating a better health status and quality of life. D-VRd, subcutaneous daratumumab plus bortezomib/ lenalidomide/dexamethasone; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; SE, standard error; VRd, bortezomib/lenalidomide/dexamethasone.
非 KM Figure